157 related articles for article (PubMed ID: 28452844)
1. Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor.
Raheja H; Kumar V; Kamholz S; Hollander G; Shani J
Am J Ther; 2018; 25(4):e508-e509. PubMed ID: 28452844
[No Abstract] [Full Text] [Related]
2. Sacubitril/Valsartan-Associated Small Bowel Ileus.
Hanefeld-Fox L; Jimenez L; Heflin R; Quiel L
Am J Ther; 2018; 25(6):e705-e706. PubMed ID: 29324464
[No Abstract] [Full Text] [Related]
3. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
[TBL] [Abstract][Full Text] [Related]
4. Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
Owens RE; Oliphant CS
J Am Board Fam Med; 2017; 30(4):556-557. PubMed ID: 28720639
[TBL] [Abstract][Full Text] [Related]
5. Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure.
Adie S; Bitar A; Hanigan S; Pogue K; Koelling T; Dorsch M
J Card Fail; 2019 May; 25(5):412-413. PubMed ID: 30904558
[No Abstract] [Full Text] [Related]
6. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
Kim YS; Brar S; D'Albo N; Dey A; Shah S; Ganatra S; Dani SS
Cardiovasc Drugs Ther; 2022 Oct; 36(5):915-924. PubMed ID: 34125356
[TBL] [Abstract][Full Text] [Related]
7. Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
Owens AT; Brozena S; Jessup M
Annu Rev Med; 2017 Jan; 68():41-49. PubMed ID: 27686019
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
9. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
Dani SS; Ganatra S; Vaduganathan M
Int J Cardiol; 2021 Jan; 323():188-191. PubMed ID: 32841619
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
Rodgers JE
Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
[TBL] [Abstract][Full Text] [Related]
11. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
[TBL] [Abstract][Full Text] [Related]
12. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
Pogge EK; Davis LE
Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
McCormack PL
Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
[TBL] [Abstract][Full Text] [Related]
15. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
16. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
17. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Tyler JM; Teerlink JR
Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril-valsartan: novel therapy for heart failure.
Sehn E; McDonald T; Lindblad AJ
Can Fam Physician; 2017 Sep; 63(9):697. PubMed ID: 28904036
[No Abstract] [Full Text] [Related]
19. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril + valsartan (Entresto°) in chronic heart failure.
Prescrire Int; 2017 Feb; 26(179):33-37. PubMed ID: 30726626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
